Stock listing
GPW:BCX Bioceltix SA Akcje
Home listing (GPW) of Bioceltix SA
Follow Bioceltix SA into a list and get an email when it puts out news.
Share price · GPW:BCX
63.40 PLN -2.00 (-3.1%)
Close on Nov 20, 2026
- Day range
- 63.30 – 66.00 PLNNov 20, 2026
- Volume
- 4,984 sharesNov 20, 2026
- Market cap
- 350.7M PLNAt the close on Nov 20, 2026 · price × 5.53M shares outstanding
- 52-week range
- 57.50 – 99.00 PLNLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 450,544 PLNMedian day 3,413 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| GPW:BCX · Home | 63.40 PLN | -2.00 (-3.1%) | 4,984 | 66.00 | 66.00 | 63.30 | 65.40 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · GPW:BCX · PLN, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 63.40 | -2.00 | -3.1% | 66.00 | 66.00 | 63.30 | 4,984 | |
| 65.40 | -1.60 | -2.4% | 67.00 | 67.00 | 65.10 | 3,201 | |
| 67.00 | -1.80 | -2.6% | 68.70 | 69.00 | 66.30 | 3,242 | |
| 68.80 | -1.30 | -1.9% | 70.70 | 70.70 | 66.80 | 3,479 | |
| 70.10 | +4.40 | +6.7% | 66.00 | 72.00 | 65.60 | 10,089 | |
| 65.70 | -2.60 | -3.8% | 68.30 | 68.30 | 65.00 | 7,941 | |
| 68.30 | -0.40 | -0.6% | 68.20 | 68.50 | 67.70 | 1,107 | |
| 68.70 | -0.30 | -0.4% | 69.50 | 69.50 | 67.80 | 1,346 | |
| 69.00 | +1.00 | +1.5% | 68.60 | 70.20 | 67.40 | 5,822 | |
| 68.00 | -2.70 | -3.8% | 69.80 | 70.60 | 67.70 | 2,875 | |
| 70.70 | +2.40 | +3.5% | 69.00 | 70.70 | 68.20 | 2,098 | |
| 68.30 | -0.70 | -1.0% | 69.00 | 69.20 | 67.80 | 4,006 | |
| 69.00 | -1.00 | -1.4% | 69.50 | 71.20 | 68.50 | 3,642 | |
| 70.00 | +0.30 | +0.4% | 69.80 | 70.10 | 67.80 | 7,305 | |
| 69.70 | -2.30 | -3.2% | 72.00 | 72.00 | 69.30 | 12,167 | |
| 72.00 | -0.90 | -1.2% | 73.00 | 75.30 | 71.10 | 20,273 | |
| 72.90 | +5.10 | +7.5% | 68.90 | 73.00 | 66.60 | 33,965 | |
| 67.80 | +4.90 | +7.8% | 64.70 | 69.00 | 63.20 | 12,686 | |
| 62.90 | +0.40 | +0.6% | 63.50 | 64.00 | 62.50 | 4,163 | |
| 62.50 | -2.30 | -3.5% | 64.80 | 65.00 | 61.60 | 7,006 | |
| 64.80 | +5.30 | +8.9% | 59.50 | 64.90 | 59.00 | 11,139 | |
| 59.50 | -2.80 | -4.5% | 62.70 | 62.70 | 57.50 | 46,257 | |
| 62.30 | -2.40 | -3.7% | 64.60 | 64.70 | 60.80 | 18,608 | |
| 64.70 | -2.60 | -3.9% | 67.00 | 67.00 | 62.60 | 18,577 | |
| 67.30 | -1.90 | -2.7% | 68.70 | 69.60 | 62.50 | 29,329 | |
| 69.20 | -0.40 | -0.6% | 69.00 | 69.80 | 68.90 | 3,413 | |
| 69.60 | -0.80 | -1.1% | 70.10 | 70.70 | 68.80 | 5,351 | |
| 70.40 | -2.50 | -3.4% | 71.80 | 71.90 | 70.00 | 15,549 | |
| 72.90 | +1.60 | +2.2% | 71.00 | 72.90 | 71.00 | 2,533 | |
| 71.30 | -0.80 | -1.1% | 72.20 | 74.40 | 71.30 | 2,300 | |
| 72.10 | +1.30 | +1.8% | 71.00 | 75.90 | 71.00 | 5,330 | |
| 70.80 | -1.00 | -1.4% | 71.90 | 71.90 | 70.70 | 10,541 | |
| 71.80 | -1.70 | -2.3% | 73.40 | 73.40 | 71.20 | 9,588 | |
| 73.50 | -2.10 | -2.8% | 75.10 | 75.90 | 73.40 | 5,763 | |
| 75.60 | -0.30 | -0.4% | 75.90 | 76.00 | 75.10 | 1,236 | |
| 75.90 | -0.10 | -0.1% | 76.00 | 76.00 | 75.00 | 982 | |
| 76.00 | +1.10 | +1.5% | 75.80 | 76.00 | 74.40 | 1,905 | |
| 74.90 | +0.50 | +0.7% | 74.90 | 75.10 | 74.50 | 1,468 | |
| 74.40 | -0.40 | -0.5% | 74.80 | 75.40 | 74.40 | 2,575 | |
| 74.80 | -1.20 | -1.6% | 75.90 | 75.90 | 74.80 | 2,520 | |
| 76.00 | +0.50 | +0.7% | 76.00 | 76.00 | 74.70 | 1,144 | |
| 75.50 | +0.20 | +0.3% | 75.20 | 75.60 | 74.60 | 3,675 | |
| 75.30 | +0.30 | +0.4% | 75.00 | 76.00 | 74.20 | 4,557 | |
| 75.00 | -1.00 | -1.3% | 76.10 | 76.10 | 75.00 | 5,774 | |
| 76.00 | +0.60 | +0.8% | 75.70 | 76.10 | 75.30 | 1,878 | |
| 75.40 | -0.20 | -0.3% | 75.80 | 75.90 | 75.30 | 1,762 | |
| 75.60 | -0.40 | -0.5% | 76.80 | 76.80 | 75.60 | 1,056 | |
| 76.00 | -0.40 | -0.5% | 76.80 | 77.30 | 76.00 | 1,593 | |
| 76.40 | -0.60 | -0.8% | 77.00 | 77.30 | 76.40 | 2,370 | |
| 77.00 | -0.30 | -0.4% | 77.10 | 77.40 | 76.60 | 3,389 | |
| 77.30 | -0.10 | -0.1% | 77.80 | 77.80 | 76.80 | 1,908 | |
| 77.40 | -0.10 | -0.1% | 77.50 | 77.90 | 76.80 | 1,605 | |
| 77.50 | 0.00 | 0.0% | 77.50 | 78.20 | 77.00 | 3,630 | |
| 77.50 | -1.70 | -2.1% | 78.50 | 78.50 | 74.50 | 12,090 | |
| 79.20 | -0.20 | -0.3% | 79.00 | 79.50 | 78.70 | 4,100 | |
| 79.40 | +0.20 | +0.3% | 78.90 | 79.60 | 78.50 | 2,914 | |
| 79.20 | -0.10 | -0.1% | 79.30 | 79.30 | 78.60 | 2,926 | |
| 79.30 | -0.70 | -0.9% | 80.00 | 80.00 | 79.00 | 2,791 | |
| 80.00 | 0.00 | 0.0% | 79.50 | 80.10 | 79.00 | 1,636 | |
| 80.00 | -0.90 | -1.1% | 80.90 | 80.90 | 79.50 | 1,325 | |
| 80.90 | +0.40 | +0.5% | 80.50 | 81.20 | 79.60 | 3,176 | |
| 80.50 | +0.80 | +1.0% | 80.10 | 80.70 | 79.60 | 1,813 | |
| 79.70 | -0.30 | -0.4% | 80.90 | 80.90 | 79.10 | 2,608 | |
| 80.00 | -0.90 | -1.1% | 80.10 | 80.90 | 79.10 | 3,811 | |
| 80.90 | -0.30 | -0.4% | 80.60 | 81.20 | 80.00 | 2,025 |
- Ticker
- GPW:BCX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- GPW
- Currency
- PLN
What changed lately
Latest news release · Jun 10, 2026
Bioceltix Receives Permit For Biological Veterinary Drugs Facility
Latest deck · Mar 31, 2026
Conference Presentation (March 2026)
Conference · 18 slides
Latest news
Bioceltix Receives Permit For Biological Veterinary Drugs Facility
Jun 10, 2026
Closed 87.90 (-0.1%) on Jun 10, 2026
BCX: Strong cash position, regulatory progress, and major investments mark Q1 2026 pre-commercial phase
May 29, 2026
Closed 85.00 (+3.5%) on Jun 1, 2026
BCX: Advanced cell therapy pipeline, secured funding, and strengthened readiness for commercialization
Apr 28, 2026
Closed 87.60 (-1.1%) on Apr 29, 2026
Bioceltix Signs Advisory Agreement For FDA Regulatory Support
Apr 14, 2026
Closed 81.50 (+0.6%) on Apr 14, 2026
BCX: Pioneering stem cell therapies for pets, with proven efficacy and major market expansion plans
Mar 31, 2026
Closed 76.40 (+7.6%) on Mar 31, 2026
Bioceltix Gets GMP Certificate For Wroclaw Veterinary Medicine Facility
Feb 18, 2026
Closed 86.70 (-0.5%) on Feb 18, 2026
Bioceltix Q3 Net Loss At 4.4 Mln Zlotys
Dec 1, 2025
Closed 89.80 (0.0%) on Dec 1, 2025
Bioceltix SA on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 7 in the last 12 months · 11 in all · newest Jun 10, 2026 · oldest 2025
- Decks
- 4 decks · latest Mar 31, 2026
Where Bioceltix SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| GPW:BCX · Home listing · This page | GPW | Poland | PLN |
| LS Exchange:A3C7NH | LS Exchange | Germany | EUR |
| Frankfurt:XI3 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A3C7NH | Lang & Schwarz | Germany | EUR |
Valuation
Price/book 5.6× against a median of 1.7×: 9th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 294.1M PLN
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 5.6×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Bioceltix SA · GPW:BCX | US$86.38M | US$72.43M | n/a | n/a | n/a | 5.6× | n/a | 0.0× | n/a |
| Cumberland Pharmaceuticals Inc. · NASDAQ:CPIX | US$87.57M | US$11.59M | 1.3× | 0.5× | n/a | 1.2× | 273.7% | 0.1× | 0.72 |
| Retension Pharmaceuticals, Inc. · NASDAQ:RTSN | US$87.57M | US$78.38M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Equillium, Inc. · NASDAQ:EQ | US$87.26M | US$34.71M | n/a | n/a | n/a | 1.7× | n/a | 0.0× | 1.31 |
| Upstream Bio, Inc. · NASDAQ:UPB | US$87.15M | −US$119.4M | n/a | −41.6× | n/a | 0.4× | n/a | 0.0× | 1.95 |
| Senhwa Biosciences Inc · TPEX:6492 | US$86.77M | US$67.44M | n/a | 2,117× | n/a | 4.6× | n/a | 0.0× | n/a |
| Perspective Therapeutics, Inc. · AMEX:CATX | US$86.05M | −US$114.1M | n/a | −570× | n/a | 0.3× | n/a | 0.0× | 1.47 |
| Pharmosa Biopharm Inc. · TPEX:6875 | US$86.04M | US$62.27M | n/a | 38.5× | n/a | 2.1× | −658.1% | 0.1× | n/a |
| Formosa Pharmaceuticals, Inc. · TWSE:6838 | US$85.43M | US$48.52M | n/a | 30.4× | n/a | 2.0× | −361.4% | 0.0× | n/a |
| Genome & Co. · KRX:314130 | US$85.27M | US$37.21M | n/a | 2.0× | n/a | 1.6× | −169.1% | 0.0× | n/a |
| Anixa Biosciences, Inc. · NASDAQ:ANIX | US$84.82M | US$70.96M | n/a | n/a | n/a | 5.9× | n/a | 0.0× | 1.45 |
| Median of the others | US$86.41M | US$42.86M | 1.3× | 2.0× | 1.7× | −265.3% | 0.0× | 1.45 |
Forecasts
Analysts' consensus from EODHD, read Nov 21, 2026. Not 6ix's view and not investment advice.
- Price target
- 119.00 PLN · Analysts' mean
- EPS, year to Dec 2026
- -3.30 · 1 analyst
Team and board
| Officer | Role |
|---|---|
| Łukasz Bzdzion | CEO / President of the Management Board |
| Andrij Włach | Chief Financial Officer, Authorized Signatory (Commercial Proxy) |
| Grzegorz Ostropolski | Chief Operating Officer, Authorized Signatory (Commercial Proxy) |
| Lahoud Touma | Chief Technology Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2025 | Apr 28, 2025 · After close | +4.1% |
| Q3 2024 | Nov 25, 2024 · After close | +2.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Conference Presentation (March 2026) | Conference | 18 slides | Mar 31, 2026 |
| Investor Presentation (December 2025) | Investor deck | 8 slides | Dec 10, 2025 |
| Investor Presentation (November 2025) | Investor deck | 8 slides | Nov 30, 2025 |
| IPO Roadshow (March 2021) | IPO roadshow | 32 slides | March 2021 |
Financings
| Raise | Date |
|---|---|
| Strategic investment of o series shares Announced: PLN 87 a share Buyers: Kvarko Group (New O series shares to be offered in a private subscription as part of an investment deal) | Oct 20, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in PLN
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 10.8K | 1.50K | 9.20K |
| Cost of revenue | 680.1K | 574.4K | 1.04M | 445.4K | 377.0K | 3.88M | 3.48M | 1.82M |
| Gross profit | -680.1K | -574.4K | -1.04M | -445.4K | -377.0K | -3.87M | -3.48M | -1.81M |
| Research and development | 3.50M | 6.36M | 3.84M | 1.28M | 1.93M | |||
| Selling, general and administrative | 9.43M | 5.21M | 2.94M | 1.95M | 2.06M | |||
| Operating income | -17.3M | -18.8M | -15.8M | -9.67M | -6.21M | -3.99M | -3.78M | -1.92M |
| Depreciation and amortization | 680.1K | 574.4K | 434.8K | 445.4K | 377.0K | 222.9K | 48.4K | 14.0K |
| EBITDA | -16.6M | -18.3M | -15.4M | -9.23M | -5.84M | -3.77M | -3.73M | -1.91M |
| Interest expense | 208.9K | 254.2K | 33.6K | 31.5K | 22.9K | 17.0K | 20.9K | 7.25K |
| Income before tax | -15.2M | -14.9M | -13.7M | -8.97M | -4.36M | -2.37M | -1.60M | -775.7K |
| Income tax | -15.4K | 30.5K | -5.27K | -46.1K | 41.5K | -17.0K | -5 | |
| Net income | -15.2M | -14.9M | -13.7M | -8.92M | -4.40M | -2.35M | -1.60M | -775.7K |
| Earnings per share, basic | -3.03 | -3.28 | -3.49 | -2.67 | -1.39 | -0.95 | -0.49 | -0.24 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 68.4M | 33.6M | 9.31M | 4.12M | 6.05M | 3.20M | 1.10M | 1.57M |
| Receivables | 2.73M | 4.97M | 167.5K | 27.6K | 444.3K | 191.0K | 635.5K | 230.0K |
| Inventory | 0 | 14.0K | 8.62K | 0 | 0 | 11.8K | 5.48K | 1 |
| Current assets | 71.3M | 39.4M | 11.2M | 4.36M | 6.51M | 3.42M | 1.75M | 1.81M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | |||
| Total assets | 75.6M | 41.9M | 12.7M | 5.99M | 8.20M | 4.80M | 3.23M | 3.30M |
| Accounts payable | 640.6K | 1.49M | 1.21M | 959.1K | 287.8K | 345.1K | 57.0K | 140.2K |
| Current liabilities | 2.19M | 3.20M | 2.14M | 2.25M | 1.91M | 1.33M | 1.32M | 1.73M |
| Long-term debt | 0 | 0 | ||||||
| Total debt | 314.9K | 823.9K | 175.1K | 293.9K | 530.8K | 104.2K | 165.0K | |
| Total liabilities | 2.36M | 3.44M | 2.27M | 2.50M | 2.20M | 1.48M | 1.32M | 1.73M |
| Shareholders' equity | 73.3M | 38.4M | 10.5M | 5.15M | 6.00M | 3.32M | 1.91M | 1.57M |
| Shares outstanding | 5.00M | 4.54M | 3.92M | 3.34M | 3.16M | 2.47M | 3.29M | 3.29M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -12.1M | -17.7M | -14.7M | -7.91M | -4.04M | -1.51M | -1.67M | -1.79M |
| Capital spending | -1.97M | -242.8K | -458.4K | -351.7K | -5.98K | -13.9K | -179.7K | -523.2K |
| Free cash flow | -14.1M | -18.0M | -15.2M | -8.26M | -4.05M | -1.53M | -1.85M | -2.31M |
| Cash from investing | -1.97M | -84.2K | -458.4K | -351.7K | 134.1K | -13.9K | -179.7K | -523.2K |
| Cash from financing | 48.8M | 42.1M | 20.4M | 6.32M | 6.76M | 3.63M | 1.38M | 1.50M |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | |||
| Change in cash | 34.8M | 24.3M | 5.19M | -1.93M | 2.85M | 2.10M | -469.8K | -814.1K |
Cap table
Built by 6ix from Bioceltix SA’s releases · as of Oct 20, 2025
- Common shares
- 5,532,253
- Fully diluted
- 5,532,253
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 5,532,253 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 5,532,253 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Andrij Włach | Chief Financial Officer, Authorized Signatory (Commercial Proxy) · Since at least Nov 5, 2026 |
| Grzegorz Ostropolski | Chief Operating Officer, Authorized Signatory (Commercial Proxy) · Since at least Nov 5, 2026 |
| Lahoud Touma | Chief Technology Officer · Since at least Nov 5, 2026 |
| Łukasz Bzdzion | CEO / President of the Management Board · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Bioceltix SA.